— Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET — ROCKVILLE, Md., April 30, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational […]
— Conference Call Scheduled for Wednesday, February 27, 2019 at 4:30 p.m. EST — ROCKVILLE, Md., Feb. 19, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for
ROCKVILLE, Md., Aug. 29, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by
October 16, 2025 08:11 ET ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced its entry into a warrant inducement agreement with existing institutional investors of
October 16, 2025 15:23 ET ROCKVILLE, Maryland, Oct. 16, 2025 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), («Theriva» o la «empresa»), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado su participación en un acuerdo de incentivos para el
October 06, 2025 12:30 ET – Los datos preclínicos del VCN-12, el próximo candidato del programa de investigación VCN-X de Theriva, destacan un novedoso mecanismo de acción con potencial para mejorar significativamente los efectos antitumorales – – La monografía previa al encuentro de la ESGCT incluye datos preclínicos que demuestran la viabilidad de la administración
October 06, 2025 08:00 ET – Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects – – Pre-ESGCT meeting monograph includes preclinical data demonstrating the feasibility of VCN-01 intracranial administration for the potential treatment of brain tumors –
August 11, 2025 08:00 ET – Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October – – VCN-01 demonstrates potential in retinoblastoma with Phase 1 safety and clinical outcome data presented at the
August 11, 2025 08:00 ET – Se han publicado datos preliminares positivos del estudio de Fase 2b de VIRAGE de VCN-01 (zabilugene almadenorepvec); los datos ampliados se presentarán en el Congreso de la European Society for Medical Oncology (ESMO) de 2025 que tendrá lugar en octubre – – VCN-01 muestra su potencial en el retinoblastoma
May 27, 2025 08:00 ET – Los resultados clínicos y de seguridad del estudio de Fase 1 del VCN-01 (zabilugene almadenorepvec) en pacientes con retinoblastoma refractario se presentarán en una sesión de pósteres en la reunión anual de la Sociedad Americana de Oncología Clínica (ASCO) en Chicago el sábado 31 de mayo de 2025 –
